What is the first‑line pharmacologic therapy for an adult or adolescent with persistent asthma?

First-Line Treatment for Persistent Asthma in Adults and Adolescents

Low-dose inhaled corticosteroids (ICS) are the first-line pharmacologic therapy for adults and adolescents with persistent asthma, as they are the most consistently effective single long-term controller medication for improving symptoms, lung function, and reducing exacerbations. 1, 2

Primary Treatment Recommendation

• Initiate low-dose ICS as daily maintenance therapy for all patients with persistent asthma (defined as symptoms more than twice weekly, nighttime awakenings more than twice monthly, or SABA use more than twice weekly). 1, 2, 3

• Recommended starting doses include:

  • Fluticasone propionate 100-250 µg/day, or
  • Budesonide 200-400 µg/day, administered twice daily 2

• ICS demonstrate superior efficacy compared to all other single controller medications including leukotriene receptor antagonists, theophylline, and cromones in improving symptom scores, lung function, and reducing exacerbations. 1, 2

Alternative Approach for Adherence Concerns

• For patients ≥12 years who may struggle with daily medication adherence, consider as-needed ICS plus SABA taken concomitantly during symptom worsening as an acceptable alternative to daily low-dose ICS. 2, 3

• This approach reduces total ICS exposure while providing non-inferior control of exacerbations, though it may be less effective for day-to-day symptom control compared with daily low-dose ICS. 2

• Note that no fixed-dose combined ICS/SABA inhaler is commercially available in the United States, requiring use of separate inhalers. 2

Second-Line Controller Options

• Leukotriene receptor antagonists (montelukast, zafirlukast) are alternative second-line options for mild persistent asthma when ICS are not appropriate, though they are less effective than ICS. 1, 2

• These agents offer easier administration and higher compliance rates, making them useful when adherence to inhaled therapy is problematic. 1

• Other alternatives include cromolyn, nedocromil, and sustained-release theophylline, but these are not preferred due to inferior efficacy and (for theophylline) the need for serum monitoring. 2

Critical Safety Considerations

• Never use long-acting beta-agonists (LABAs) as monotherapy for persistent asthma, as this significantly increases the risk of severe exacerbations and asthma-related mortality. 1, 3

• LABAs must always be combined with an inhaled corticosteroid, either in a single combination inhaler or as separate devices. 1, 3

Proper Inhaler Technique

• Use a spacer or valved holding chamber with metered-dose inhalers to increase lung deposition and reduce oropharyngeal side effects like thrush. 2

• Instruct patients to rinse their mouth and spit after each inhalation to minimize local adverse effects. 2

Indicators for Treatment Intensification

• SABA use more than twice weekly for symptom relief (excluding exercise-induced bronchospasm prevention) indicates inadequate control and need to step up therapy. 1, 2, 3

• Nighttime awakenings more than twice monthly also signal the need for treatment intensification. 3

• Using more than one SABA canister per month is another indicator of poor control. 2

When to Add Second Controller

• If asthma remains uncontrolled after 2-6 weeks on low-dose ICS, adding a LABA to low-dose ICS is the preferred next step for patients ≥12 years, providing greater improvement in lung function, symptoms, and exacerbation reduction compared to increasing ICS dose alone. 1, 2

• Both options (adding LABA or increasing ICS dose) should be given equal weight, though LABA addition is preferred for most patients ≥12 years. 1, 3

Monitoring Strategy

• Assess treatment response at 2-6 week intervals when initiating or stepping up therapy. 2

• Perform spirometry at initial assessment, after treatment stabilization, and at least every 1-2 years. 2

• Verify proper inhaler technique before escalating therapy, as poor technique is a common cause of apparent treatment failure. 2

Common Pitfalls to Avoid

• Do not delay ICS initiation in persistent asthma, as early intervention improves long-term outcomes and prevents progressive airway remodeling. 2, 3

• Avoid using regular chronic SABA as a long-term management strategy, as this masks poorly controlled persistent asthma and delays appropriate treatment escalation. 2

• Do not escalate to high-dose ICS without first considering adding a second controller, as the dose-response curve for ICS is relatively flat with minimal additional benefit at high doses but increased systemic side effects. 3